Cutler Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,700
| Closed | -$103K | – | 4520 |
|
|
2023
Q2 | $103K | Buy |
+2,700
| New | +$69.3K | 0.01% | 905 |
|
|
2020
Q4 | – | Sell |
-3,040
| Closed | -$36K | – | 5688 |
|
|
2020
Q3 | $36K | Buy |
3,040
+2,000
| +192% | +$26.8K | ﹤0.01% | 2023 |
|
|
2020
Q2 | $12K | Hold |
1,040
| – | – | ﹤0.01% | 2781 |
|
|
2020
Q1 | $14K | Hold |
1,040
| – | – | ﹤0.01% | 2543 |
|
|
2019
Q4 | $6K | Hold |
1,040
| – | – | ﹤0.01% | 2992 |
|
|
2019
Q3 | $5K | Hold |
1,040
| – | – | ﹤0.01% | 3094 |
|
|
2019
Q2 | $8K | Hold |
1,040
| – | – | ﹤0.01% | 2859 |
|
|
2019
Q1 | $20K | Hold |
1,040
| – | – | ﹤0.01% | 2070 |
|
|
2018
Q4 | $13K | Buy |
1,040
+620
| +148% | +$12.4K | ﹤0.01% | 2403 |
|
|
2018
Q3 | $15K | Sell |
420
-180
| -30% | -$5.78K | ﹤0.01% | 2430 |
|
|
2018
Q2 | $21K | Sell |
600
-20
| -3% | -$767 | ﹤0.01% | 2171 |
|
|
2018
Q1 | $28K | Hold |
620
| – | – | ﹤0.01% | 2051 |
|
|
2017
Q4 | $23K | Hold |
620
| – | – | ﹤0.01% | 2466 |
|
|
2017
Q3 | $33K | Sell |
620
-180
| -23% | -$10.7K | ﹤0.01% | 2659 |
|
|
2017
Q2 | $45K | Sell |
800
-590
| -42% | -$29.6K | ﹤0.01% | 2607 |
|
|
2017
Q1 | $74K | Sell |
1,390
-604
| -30% | -$34.1K | ﹤0.01% | 2037 |
|
|
2016
Q4 | $113K | Hold |
1,994
| – | – | ﹤0.01% | 1803 |
|
|
2016
Q3 | $123K | Sell |
1,994
-1,080
| -35% | -$76.3K | 0.01% | 1648 |
|
|
2016
Q2 | $173K | Buy |
3,074
+200
| +7% | +$12.2K | 0.01% | 1230 |
|
|
2016
Q1 | $184K | Buy |
+2,874
| New | +$232K | 0.01% | 1072 |
|
Cutler Group's KDNY Position: Q3 2023 in Review
Cutler Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 2,700 shares — an estimated $103K sold.
Cutler Group first reported a position in KDNY in Q1 2016 and held it in 20 quarters. The position peaked at $184K in Q1 2016. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Cutler Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 2,700 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $103K.
- Cutler Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 20 quarters.
- Cutler Group's Chinook Therapeutics, Inc. Common Stock position peaked at $184K in Q1 2016.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.